Menu
Menu
Menu
Menu
Brand Name :
Orenitram,remodulin
Synonyms :
treprostinil
Class :
Pulmonary hypertension, prostacyclin analogues
ADVERTISEMENT
Brand Name :
Orenitram,remodulin
Synonyms :
treprostinil
Class :
Pulmonary hypertension, prostacyclin analogues
Dosage Forms & Strengths
Extended-release tablets:
0.125mg,0.25mg,1mg,2.5mg,5mg
Injectable solution
1mg/ml
2.5mg/ml
5mg/ml
10mg/ml
pulmonary Arterial Hypertension
Extended-release tablets:
Initial dose: 0.25 mg orally every 12 hours or 0.125 mg every 8 hours
Maintenance dose: Increase 0.125 mg 3 times a day every 3 to 4 days or increase 0.25 or 0.5 mg twice a day
Inhalation:
Initial dose: 4 times a day, three breaths (18 mcg) each treatment session; if not tolerated, reduce to 1 or 2 breaths; increase to 3 breaths as tolerated
Maintenance dose: Once the intended dose of 9 breathes (54 mcg) per treatment session is attained, increase by an additional three breaths at about 1-to-2-week intervals as tolerated
Maximum dose: 4 times daily treatment sessions of 9 breaths (54 mcg)
Injectable
Initial dose: Continuous subcutaneous or intravenous infusion of 1.25 ng/kg/min; if this dosage is intolerable, lower it to 0.625 ng/kg/min
Maintenance dose: During the first four weeks, increase the infusion rate by 1.25 ng/kg/min each week. Then, for the remaining four weeks, increase the rate by 2.5 ng/kg/min each week
Dosage Forms & Strengths
Injectable solution
1mg/ml
2.5mg/ml
5mg/ml
10mg/ml
pulmonary Arterial Hypertension
<18 years: Safety and efficacy not established
Injectable (> 16 years)
Initial dose: 1.25 ng/kg/min subcutaneous/Intravenous infusion
Do not increase more than 1.25 ng/kg/min every week for four weeks
Oral tablet
Initial dose: 0.25mg orally, twice a day. Increase up to 0.5mg twice daily every 3-4 days
Maximum dose: 3.4mg twice a day
Refer adult dosing
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect
may enhance the serum concentration of CYP2C8 inhibitors
may increase the QTc prolonging effect
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may increase the QTc prolonging effect of QT-prolonging agents
may enhance the effects of the other by pharmacodynamic synergism
it may enhance the QTc-prolonging effect of terfenadine
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the levels of each other by decreasing metabolism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the effect of each other through anticoagulation
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with haloperidol
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
Frequency defined:
>10%
Nausea
Vasodilation
Reaction at the infusion site
Headache
Rash
Diarrhea
1-10%
Edema
Hypotension
Dizziness
Pruritis
Frequency not defined
Cellulitis
Angioedema
Bone pain
Restlessness
Hemoptysis
Post-marketing reports
Vomiting
Arthralgia
Pain extremity
Dyspepsia
Myalgia
Gastrointestinal effects
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: Treprostinil
Pronounced: tre·pros·tinil
Why do we use Treprostinil?
It is a prostacyclin vasodilator used to treat pulmonary arterial hypertension by relieving exercise-related symptoms.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
